News UK biotech Dunad inks $1.3bn Novartis deal for its protein d... In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.